Contrast, coagulation, and fibrinolysis.
Some adverse clinical effects of intravascular radiologic contrast agents have been attributed to their interference with the normal hemostatic processes. This study compares the effects of the low osmolality agents with those of the conventional agents by in vitro studies of platelet function, fibrin formation, and fibrinolytic activation. In various degrees, all the contrast agents studied inhibit platelet aggregation and fibrin formation but show virtually no direct activation of fibrinolysis. The new low osmolality agents generally show lesser inhibitory effects on the hemostatic mechanisms. Some clinical implications are discussed.
D001777:Blood Coagulation / Q000187:drug effects*; D001792:Blood Platelets / Q000187:drug effects*; D003287:Contrast Media / Q000633:toxicity*; D005337:Fibrin / Q000096:biosynthesis; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D007471:Ioglycamic Acid / Q000031:analogs & derivatives / Q000633:toxicity; D007472:Iohexol; D007479:Iopamidol; D007483:Iothalamic Acid / Q000031:analogs & derivatives / Q000633:toxicity; D007485:Ioxaglic Acid; D009994:Osmolar Concentration; D010974:Platelet Aggregation / Q000187:drug effects; D010979:Platelet Function Tests; D014283:Triiodobenzoic Acids / Q000633:toxicity
D003287:Contrast Media; D014283:Triiodobenzoic Acids; C008447:methylglucamine ioglycamide; D007483:Iothalamic Acid; D007472:Iohexol; D005337:Fibrin; D007471:Ioglycamic Acid; D007479:Iopamidol; D007485:Ioxaglic Acid